Drug intelligence / Profile preview

ENV-308

Development stage: Preclinical
Lead developer: Enveda Biosciences
Modality: Small Molecules
Administration: Oral

Overview

ENV-308 is a nature-inspired small-molecule drug candidate developed by Enveda Biosciences. Discovered using the company's proprietary AI and metabolomics platform, which identifies therapeutic compounds from natural sources, ENV-308 is being developed for the treatment of obesity and fibrosis. As of early 2025, the program is in the preclinical stage, with Enveda planning to advance the candidate into clinical trials during 2025.

Targets

TL1A (TNF-like cytokine 1A)

Beyond the preview

Go deeper on ENV-308.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENV-308.

Explore the full profile